Fluorouracil oral emulsion

This product has a strong cytotoxic effect in vitro and has a significant anti-tumor effect on a variety of transplanted tumors in vivo. It is first converted into 5-fluoro-2-deoxyuridine by enzymes in the body, which inhibits thymidine synthetase and blocks the conversion of deoxyuridine nucleotides into deoxythymidine nucleotides, thereby inhibiting the biosynthesis of DNA. In addition, it can also be incorporated into RNA, and inhibit RNA synthesis by preventing uracil and orotic acid from incorporating into RNA. This product is a cell cycle-specific drug that mainly inhibits tumor cells in the S phase.

This product is an oral liquid preparation of fluorouracil emulsion, and the fluorouracil (C4H3FN2O2) content should be 90.0% to 110.0% of the labeled amount.

This product is a white milky solution.

Used for digestive system adenocarcinoma, including gastric cancer, pancreatic cancer, intestinal cancer, biliary tract cancer, and liver metastatic adenocarcinoma.

Oral administration: 10 ml each time, 3 times a day, 30 days as a course of treatment, total amount is 10-15g.

1. Nausea, loss of appetite or vomiting, usually not serious with most doses, oral mucosal inflammation or ulcers, abdominal discomfort or diarrhea, peripheral blood leukopenia is common (mostly reaches the lowest point within 2 to 3 weeks after the start of the course of treatment, and returns to normal after about 3-4 weeks), thrombocytopenia is rare, and cough, shortness of breath or cerebellar ataxia are extremely rare. 2. Long-term use can lead to nervous system toxicity. 3. Occasionally, myocardial ischemia after medication may occur, and angina pectoris and electrocardiogram changes may occur. If confirmed cardiovascular reactions (arrhythmia, angina pectoris, ST segment changes) occur, fluorouracil can no longer be used because of the risk of sudden death.

1. Pregnant women within 3 months of pregnancy are prohibited from using this product. 2. Patients with varicella or herpes zoster are prohibited from using this product. 3. Women who are breastfeeding are prohibited from using this product. 4. Patients with weak constitution are prohibited from using this product.

Precautions for children: Not yet clear. Precautions for pregnancy and lactation: A very small number of people have congenital malformations due to the use of this product in the first three months of pregnancy, and it may have long-term effects on the fetus. Women are prohibited from using this drug in the first three months of pregnancy. Due to the potential mutagenicity, teratogenicity and carcinogenicity of this product and the possible toxic and side effects in infants, breastfeeding is not allowed during the use of this product. Precautions for the elderly: Not yet clear.

It has been reported that a variety of drugs can biochemically affect the anti-cancer effect or toxicity of fluorouracil. Common drugs include methotrexate, metronidazole and tetrahydrofolate. When used in combination with methotrexate, methotrexate should be given 4 to 6 hours before fluorouracil, otherwise the effect will be reduced. Giving tetrahydrofolate first and then fluorouracil can increase its efficacy. This product can generate a neurotoxic metabolite - fluorocitric acid, which can cause cerebral palsy, so it cannot be injected intrathecally. When using this product, it is not advisable to drink alcohol or use aspirin drugs at the same time to reduce the possibility of gastrointestinal bleeding. Allopurinol can reduce the bone marrow suppression caused by fluorouracil.

Keep in a dark, sealed and cool place.

60ml:1.071g

24 months

Zhejiang Ruixin Pharmaceutical Co., Ltd.

• Founded in:

  2002-01-08

• Address:

  Development Road, Tianning Industrial Zone, Liandu District, Lishui City, Zhejiang Province

• Tax NO.:

  91330000735259021T

• Registered Funds:

  50 million yuan

• Website:

  Log in to view

• Email:

  Log in to view